Agian Gene Secures Nearly RMB 200 Million in Series A Funding to Advance Multi-Platform Solutions for Precision Diagnosis of Infections

Recently, Agian Genomics announced the completion of its nearly RMB 200 million Series A financing round. The round was led by Boyi Fund, under Tasly Capital, with participation from Huaxi Fund, Jinbang Capital, Xintou Investment, Haiding Capital, Haixia Venture Capital, and other professional investment institutions, government funds, and prominent state-owned enterprises. Kaicheng Capital served as the financial advisor. The involvement of these prestigious investors will enable Agian Genomics to accelerate its technological R&D and market expansion efforts.

Agian Gene, as a leader in integrated solutions for precision diagnosis and treatment of infections, leverages its multi-platform advantages and core technologies, including mNGS and PCR, particularly its robust bioinformatics analysis system and clinical medical reporting capabilities, to formThe positive detection rate is 10 percentage points higher than the industry average.high-quality testing capabilities, rapid response efficiency, and a strong reputation for clinical services.

Notably,Agian Gene was incubated by Guangshengtang Pharmaceutical (stock code: 300436), a listed pharmaceutical company.a national-level high-tech enterprise in the biomedical sector. With over two decades of deep expertise in the antiviral field, Guangshengtang has provided Agijan with robust channel networks and expert resources in the realm of precision diagnosis and treatment of infectious diseases. The excellent experience in cultivating listed companies and the philosophy of standardized operations are ingrained in Agijan Gene’s corporate DNA. Upholding its original aspiration to serve the country through industrial development, the company pursues operational balance alongside rapid growth, aiming to deliver returns to shareholders and contribute to society.

What makes AgiGene stand out is its team’s comprehensive strength, which is truly unique in the industry. The company has assembled a group of overseas-returnee scientists and top-tier elites from the gene sector.The company’s founder possesses extensive experience in biopharmaceutical enterprise management and leads key national biotechnology industry projects and collaborations with top-tier domestic academic institutions, fostering a high-performance team that integrates strategic development, R&D, bioinformatics and medical science, clinical marketing, nationwide commercial layout, and operational management into a comprehensive, multi-dimensional framework., enabling Agian to achieve explosive growth since 2020, driven by its forward-looking vision, strong R&D capabilities, keen market insights, unique market positioning, and efficient internal management, thereby emerging as a dark horse with the highest growth trajectory and optimal profitability in the industry.

Agian Gene has been continuously engaged in independent research and development since its establishment, and has now developedPathoSeq™ Platform Based on Next-Generation Sequencing, for infections with pathogens of unknown origin, it can rapidly and comprehensively detect over 20,000 types of pathogenic microorganisms, with a high positive detection rate;SuperSens Platform Based on Quantitative Fluorescent PCR TechnologyIt offers advantages such as high timeliness and sensitivity for common clinical infections.Integrated Molecular Diagnostic Platform for Multi-Technology Infectious Disease Detection"Provide rapid, convenient, and tiered solutions tailored to diverse scenarios, comprehensively meeting clinical needs."

Currently, Agian Gene has established medical testing laboratories, R&D centers, and production bases in multiple cities, including Fuzhou, Beijing, Shanghai, Zhengzhou, Wuhan, Guangzhou, and Chongqing, with a total area of nearly 30,000 square meters. The funds from this round of financing will be used by Agian for the research and development upgrade of new technologies and further expansion of its market scale.

Zhu Yanfei, General Manager of Boyi Fund, the Lead Investorstated: “Our investment in Agian reflects, on one hand, our confidence in this industry sector. Infectious diseases have become one of the leading causes of death globally, and the timeliness, specificity, and sensitivity of traditional diagnostic methods are insufficient to meet clinical needs. Advanced biotechnologies, such as those for pathogenic microorganism detection, can effectively address these clinical pain points, indicating substantial market potential. On the other hand, we are highly optimistic about the comprehensive strengths of the Agian team. The team possesses strategic vision, demonstrates exceptional problem-solving capabilities, and holds a differentiated market position. These factors have contributed to its remarkable growth speed and trajectory. We believe that with capital support, Agian will achieve faster and more sustainable development.”

Staying true to our original aspirations, we look forward to a promising future. Empowered by capital, Agijian Gene, with its accumulated strength poised for rapid growth, is destined to become a unique standout in the high-tech biological testing sector.

Boyi Capital, established in 2015, is a highly reputable and professional investment institution jointly founded by renowned pharmaceutical enterprise Tasly Holding Group, Chongqing Huayi Group, Chongqing Industrial Guidance Fund, and other institutions. It currently manages two venture capital funds: Boyi Xintian and Boyi Qikai. Focusing on the pharmaceutical investment sector, Boyi Capital addresses pain points in the real economy and grows alongside companies in their expansion stages. Over the past five years, Boyi Capital has invested in 25 high-quality enterprises across pharmaceuticals, in vitro diagnostics (IVD), and medical devices. Six of these portfolio companies have already been listed on the Hong Kong Stock Exchange and China’s A-share market through various pathways, with several others currently undergoing listing applications.

Huahsi Fund, established in collaboration with renowned domestic investment institutions and backed by multiple listed companies in Western China, maintains offices in Chengdu and Chongqing. The firm focuses on industrial M&A, venture capital, and equity investments in sectors such as new energy, new materials, biotechnology, healthcare, new media, and high-end manufacturing. It has jointly established multiple private equity funds with local governments, well-known domestic and international enterprises, and investment institutions. The total assets under management currently exceed RMB 10 billion. Its investors include Midea Capital, Boyi Capital, Fenxiang Investment, and Dianshi Huayi. Successful investments made by the company and its partners include Neoway Technology, Bozhon Precision Industry, Kinetic, Yi Heda, Read Intelligent, Zhuocheng Huisheng, and Zhihe Bio.

Jinbang Capital is a comprehensive asset management firm focused on investing in China’s development opportunities. Founded by renowned Chinese entrepreneurs and investment professionals sharing a common vision, the firm is headquartered in Shanghai, with branch offices in Beijing, Qingdao, Quanzhou, and other cities. Jinbang Capital currently focuses primarily on two major sectors: new energy vehicles and healthcare. Since its inception, the firm has invested in more than 50 companies, with assets under management nearing RMB 10 billion. To date, nearly 20 of its portfolio companies have completed initial public offerings (IPOs), delivering strong returns to investors.

Fuzhou Xintou Venture Capital Co., Ltd. was established in March 2021, with a registered capital of RMB 3 billion. It is a wholly-owned subsidiary of Fuzhou New Area Development Investment Group Co., Ltd. (a state-owned enterprise under the Fuzhou Municipal Government). The company’s business scope includes investment activities and supply chain trading using its own funds. In 2021, it achieved an operating revenue of RMB 3 billion.

In 2021, Mr. Zhang Mingyi founded Haiding Capital in the Hainan Free Trade Zone as the actual controller, carrying forward the legacy of Haixia Assets and integrating capital network resources from Tsinghua University’s School of Economics and Management, PBC School of Finance at Tsinghua University, and Fudan University, with deep strategic investments in new energy, life sciences, general health, and consumer sectors.

Mr. Zhang Mingyi co-founded Shenzhen Haixia Asset Management Co., Ltd. in 2015 together with the founder of Hillhouse RMB Fund, serving as Managing Director and Founding Partner. The total investment scale reached RMB 3 billion. Adhering to a research-driven approach, emphasizing fundamental analysis, and upholding value investing principles, the firm aims to deliver long-term, stable returns for investors. Investment portfolio companies include NIO, Ke Holdings (Beike Zhaofang), Genetron Health, Airbnb, Wind Information, Ziroom Apartment, and Huace Film & TV.

Haixia Venture Capital Management Co., Ltd. of Fuzhou High-tech Zone is a state-owned investment enterprise directly subordinate to the Fuzhou High-tech Industrial Development Zone, a national-level high-tech zone. It focuses on investing in enterprises within the key industries, characteristic industries, and strategic emerging industries of the Fuzhou High-tech Zone. Haixia Venture Capital fully leverages the industrial promotion and guidance role of fiscal funds from the Fuzhou High-tech Zone, accelerating industrial agglomeration and upgrading, and effectively driving the high-quality economic development of the Fuzhou High-tech Zone.